PRFX - EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions | Benzinga
PainReform Ltd (NASDAQ:PRFX) announced results from new studies demonstrating the superior in-vitro release (IVR) rates of PRF-110 compared to topical post-surgical pain management products available in the market.
These findings underscore PainReform’s commitment to advancing non-opiate pain relief options and mark a significant milestone in developing long-lasting pain management solutions.
Leveraging the latest IVR technology, which automates the testing of drug release from formulations over time, PainReform conducted comprehensive studies to evaluate the performance of PRF-110.
Over a 72-hour industry-standard duration and extending to 96 hours, PRF-110 exhibited ...